{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:38:31Z","timestamp":1794008311650,"version":"4.8.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> We compared and ranked the efficacy and tolerability of multiple prophylactic treatments for vestibular migraine (VM), including \u03b2-blockers, calcium channel blockers, antiseizure medications, and antidepressants such as tricyclics and serotonin\u2013noradrenaline reuptake inhibitors.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> PubMed, Web of Science, Embase, and Cochrane Center for Clinical Trials were systematically searched for relevant randomized clinical trials (RCTs) from March 2023 to May 2023. Studies on the efficacy and tolerability of prophylactic treatments for VM were included. Efficacy was measured using the average vertigo frequency per month and dizziness handicap inventory (DHI) improvement after 3\u20136\u00a0months of treatment. Tolerability was measured by the number of patients reporting at least one adverse event (AE). Network meta-analyses were performed according to a Bayesian framework and a random-effects model based on odds ratios or mean differences (MDs) and 95% confidence intervals (CIs). A sequence of ranking probability was calculated according to the surface under the cumulative ranking (SUCRA) curve. This network meta-analysis was previously registered with PROSPERO (CRD42023422258).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Five RCTs comprising 334 patients were analyzed by synthesizing the published evidence. Considering the examined prophylactic therapies, there is significant evidence that valproate acid (VPA) is superior to placebo or abortive treatment alone (MD = \u22124.12, 95% CI = \u22128.09, \u22120.15) in reducing the frequency of vertigo. Flunarizine (MD = 20.00, 95% CI = 10.90, 29.10), valproate acid (MD = 18.88, 95% CI = 10.42, 27.34), and venlafaxine (MD = 11.48, 95% CI = 9.84, 13.12) were significantly more effective than placebo or abortive treatment in reducing DHI. VPA most strongly reduced the frequency of vertigo according to SUCRA, but it ranked third-to-last in tolerability. Flunarizine ranked best in DHI improvement but worst in tolerability. Metoprolol ranked worst for efficacy but best for tolerability.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> VPA and flunarizine reduced the frequency of vertigo and improved DHI, but they had unfavorable tolerability. The effects of metoprolol on vertigo require further study. Given the low certainty and limited sample, additional head-to-head RCTs are warranted to further confirm efficacy.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>; Identifier CRD42023422258.<\/jats:p>","DOI":"10.3389\/fphar.2023.1332973","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:14:50Z","timestamp":1703132090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Prophylactic treatments for vestibular migraine: a systematic review and network meta-analysis of randomized clinical trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Hongyuan","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/VES-2011-0428","article-title":"Migraine, vertigo and migrainous vertigo: links between vestibular and pain mechanisms","volume":"21","author":"Balaban","year":"2011","journal-title":"J. Vestib. Res. Equilib. Orientat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s13063-019-3903-5","article-title":"Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG)","volume":"20","author":"Bayer","year":"2019","journal-title":"Trials"},{"key":"B4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11910-022-01222-6","article-title":"Vestibular migraine","volume":"22","author":"Beh","year":"2022","journal-title":"Curr. neurology Neurosci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/jcbfm.1995.63","article-title":"D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study","volume":"15","author":"Br\u00fccke","year":"1995","journal-title":"J. Cereb. blood flow metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/bcp.14046","article-title":"Management of peripheral vertigo with antihistamines: new options on the horizon","volume":"85","author":"Dyhrfjeld-Johnsen","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fneur.2015.00012","article-title":"New insights into pathophysiology of vestibular migraine","volume":"6","author":"Espinosa-Sanchez","year":"2015","journal-title":"Front. neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"104587","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: their new life from hypertension to cancer and migraine","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1474-4422(13)70107-8","article-title":"Vestibular migraine: clinical aspects and pathophysiology","volume":"12","author":"Furman","year":"2013","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41588-021-00990-0","article-title":"Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles","volume":"54","author":"Hautakangas","year":"2022","journal-title":"Nat. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ Clin. Res. ed.)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-021-01234-6","article-title":"Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial","volume":"22","author":"Khani","year":"2021","journal-title":"J. headache pain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-201644","article-title":"Vestibular migraine: diagnostic criteria1","volume":"32","author":"Lempert","year":"2022","journal-title":"J. Vestib. Res. Equilib. Orientat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1526-4610.1991.hed3106388.x","article-title":"Flunarizine in migraine: a minireview","volume":"31","author":"Leone","year":"1991","journal-title":"Headache"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial","volume":"271","author":"Lepcha","year":"2014","journal-title":"Eur. archives oto-rhino-laryngology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.13201\/j.issn.2096-7993.2021.09.004","article-title":"Lin chuang er bi yan hou tou jing","volume":"35","author":"Li","year":"2021","journal-title":"wai ke za zhi = J. Clin. otorhinolaryngology, head, neck Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD010611","DOI":"10.1002\/14651858.CD010611","article-title":"Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults","volume":"2013","author":"Linde","year":"2013","journal-title":"Cochrane database Syst. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2017.00524","article-title":"The efficacy of venlafaxine, flunarizine, and valproic acid in the prophylaxis of vestibular migraine","volume":"8","author":"Liu","year":"2017","journal-title":"Front. neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1526-4610.1981.hed2106235.x","article-title":"A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine","volume":"21","author":"Louis","year":"1981","journal-title":"Headache"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/lary.25445","article-title":"Propranolol and venlafaxine for vestibular migraine prophylaxis: a randomized controlled trial","volume":"126","author":"Salviz","year":"2016","journal-title":"Laryngoscope"},{"key":"B24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/metabo13010134","article-title":"Therapeutic and toxic effects of valproic acid metabolites","volume":"13","author":"Shnayder","year":"2023","journal-title":"Metabolites"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/brain\/awac264","article-title":"Vestibular migraine treatment: a comprehensive practical review","volume":"145","author":"Smyth","year":"2022","journal-title":"Brain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ Clin. Res. ed.)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"CD015187","DOI":"10.1002\/14651858.CD015187.pub2","article-title":"Pharmacological interventions for prophylaxis of vestibular migraine","volume":"2023","author":"Webster","year":"2023","journal-title":"Cochrane database Syst. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"805","DOI":"10.13201\/j.issn.1001-1781.2016.10.012","article-title":"Lin chuang er bi yan hou tou jing wai ke za","volume":"30","author":"Yuan","year":"2016","journal-title":"zhi = J. Clin. otorhinolaryngology, head, neck Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1332973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:14:56Z","timestamp":1703132096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1332973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":29,"alternative-id":["10.3389\/fphar.2023.1332973"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1332973","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1332973"}}